NCT05464953View on ClinicalTrials.gov

Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

April 30, 2022

Conditions
Diabetic Macular Edema of Left Eye
Interventions
DRUG

Triamcinolone Acetonide

Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema

DRUG

Formulated Triamcinolone

Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate

Trial Locations (1)

34517

Ehab tharwat, Damietta

All Listed Sponsors
lead

Al-Azhar University

OTHER

NCT05464953 - Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema. | Biotech Hunter | Biotech Hunter